From the Guidelines
A patient on Ozempic (semaglutide) can typically continue taking metformin, as these medications work in complementary ways to manage blood glucose levels in people with type 2 diabetes. According to the most recent guidelines, metformin is effective and safe, and may reduce the risk of cardiovascular events and death 1. The combination of Ozempic and metformin can provide better glycemic control than either medication alone. Standard metformin dosing (500-2000 mg daily, often divided into two doses) can be maintained when adding Ozempic, which is typically injected once weekly.
Some key points to consider when taking both medications include:
- Monitoring for gastrointestinal side effects like nausea or diarrhea, which can be mitigated by gradual dose titration of metformin 1
- Regular monitoring of kidney function, as metformin is contraindicated in those with advanced renal insufficiency 2
- Considering the potential benefits of combination therapy, including reduced risk of cardiovascular events and improved glycemic control 3
It is essential to consult with a healthcare provider before making any changes to the medication regimen, as they can provide personalized guidance and monitoring. Additionally, patients should report any side effects to their healthcare provider, and adjustments to the medication regimen can be made as needed. Overall, the combination of Ozempic and metformin can be a effective and safe treatment option for patients with type 2 diabetes, as long as it is used under the guidance of a healthcare provider and with careful monitoring of potential side effects.
From the FDA Drug Label
OZEMPIC has been studied as monotherapy and in combination with metformin, metformin and sulfonylureas, metformin and/or thiazolidinedione, and basal insulin in patients with type 2 diabetes mellitus. In a 56-week, double-blind trial (NCT01930188), 1231 patients with type 2 diabetes mellitus were randomized to OZEMPIC 0. 5 mg once weekly, OZEMPIC 1 mg once weekly, or sitagliptin 100 mg once daily, all in combination with metformin (94%) and/or thiazolidinediones (6%). The potential effect of semaglutide on the absorption of co-administered oral medications was studied in trials at semaglutide 1 mg steady-state exposure. No clinically relevant drug-drug interaction with semaglutide was observed based on the evaluated medications; therefore, no dose adjustment is required when co-administered with semaglutide. Metformin and oral contraceptive drug (ethinylestradiol/levonorgestrel) were assessed at steady state.
Yes, a patient on Ozempic can still take metformin. The drug label indicates that Ozempic has been studied in combination with metformin, and no clinically relevant drug-drug interaction was observed. 4 4
From the Research
Patient Considerations
- Patients with type 2 diabetes can take Ozempic (semaglutide) in addition to metformin, as evidenced by several studies 5, 6, 7, 8.
- The combination of semaglutide and metformin has been shown to be effective in improving glycemic control and reducing body weight in patients with type 2 diabetes 5, 6, 8.
- Semaglutide has been compared to other treatments, such as sitagliptin and empagliflozin, and has been found to be superior in reducing HbA1c and body weight in patients with type 2 diabetes on metformin 6, 8.
Treatment Efficacy
- The SUSTAIN 4 trial found that semaglutide resulted in greater reductions in HbA1c and weight, with fewer hypoglycemic episodes, compared to insulin glargine in patients with type 2 diabetes on metformin 5.
- The SUSTAIN 2 trial found that semaglutide was superior to sitagliptin in improving glycemic control and reducing body weight in patients with type 2 diabetes on metformin, thiazolidinediones, or both 6.
- A patient-level meta-analysis found that once-weekly semaglutide was superior to once-daily empagliflozin in reducing HbA1c and body weight in patients with type 2 diabetes on metformin 8.
Safety Considerations
- Semaglutide has been found to be well-tolerated, with a safety profile similar to that of other GLP-1 receptor agonists 5, 6.
- The most frequently reported adverse events with semaglutide were gastrointestinal in nature, such as nausea and diarrhea 5, 6.
- A case report found that semaglutide was safe and effective in a patient with type 2 diabetes, severe obesity, and chronic myeloid leukemia, with no compromise in CML stability 9.